Nuklearmed Nucl Med
-
Nuklearmed Nucl Med · Aug 1997
[Striatal uptake of I-123-beta-CIT and I-123-IBZM in patients with extrapyramidal symptoms].
This pilot study deals with the question whether characteristic changes in local cerebral dopamine transporter function and D2-receptor binding capacity can be shown with SPET in idiopathic Parkinson syndrome (IPS) and secondary Parkinson syndrome (SPS). ⋯ It is concluded that the neurochemical changes that can be anticipated in the above diseases can be monitored with SPET. I-123-beta-CIT, however, appears to be more adequate to differentiate IPS from SPS than I-123-IBZM.